If new treatments for immune-mediated inflammatory diseases (IMIDs) are to emerge, then a radical new approach that moves the field from one that is based on clinical signs and symptoms to one that is based on immunological and molecular mechanisms is urgently needed. This requires a new way of thinking: that IMIDs should be approached as having shared common pathogenic cells and pathways, and that therapies should be targeted at these cells and processes rather than clinical features.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Robinson, D. Jr et al. Curr. Med. Res. Op. 22, 989–1000 (2006).
Krishna, M. T. et al. Eur. Respir. J. 54, 1900476 (2019).
Kuek, A., Hazleman, B. L. & Ostör, A. J. Postgrad. Med. J. 83, 251–260 (2007).
Dinse, G. E. et al. Arthrit. Rheumatol. 72, 1026–1035 (2020).
Tracey, D. et al. Pharmacol. Ther. 117, 244–279 (2008).
Wijbrandts, C. A. & Tak, P. P. Mayo Clin. Proc. 92, 1129–1143 (2017).
Corcoran, S. E., Halai, R. & Cooper, M. A. Pharmacol. Rev. 73, 968–1000 (2021).
Decout, A., Katz, J. D., Venkatraman, S. & Ablasser, A. Nat. Rev Immunol. 21, 548–569 (2021).
Buckley, C. D. Nat. Rev. Immunol. 13, 59–66 (2013).
Cárdenas-Roldán, J., Rojas-Villarraga, A. & Anaya, J.-M. BMC Med. 11, 73 (2013).
Zenewicz, L. A., Abraham, C., Flavell, R. A. & Cho, J. H. Cell 140, 791–797 (2010).
Okada, Y. et al. Nature 506, 376–381 (2014).
David, T., Ling, S. F. & Barton, A. Clin. Exp. Immunol. 193, 3–12 (2018).
Shooshtari, P., Huang, H. & Cotsapas, C. Am. J. Human. Gen. 101, 75–86 (2017).
Shen, N. et al. Nat. Rev. Rheumatol. 8, 701–709 (2012).
Worthington, J. & Silman, A. Clin. Exp. Immunol. 101, 390–392 (1995).
Tough, D. F., Tak, P. P., Tarakhovsky, A. & Prinjha, R. K. Nat. Rev. Drug Discov. 15, 835–853 (2016).
Sims, E. K. et al. Sci. Transl. Med. 13, eabc8980 (2021).
Gerlag, D. M. et al. Ann. Rheum. Dis. 78, 179–185 (2019).
Jumper, J. et al. Nature 596, 583–589 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.D.B. is a founder of Mestag with founding equity (https://mestagtherapeutics.com). L.K.M. is an employee and has shares in GSK. All other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Buckley, C.D., Chernajovsky, L., Chernajovsky, Y. et al. Immune-mediated inflammation across disease boundaries: breaking down research silos. Nat Immunol 22, 1344–1348 (2021). https://doi.org/10.1038/s41590-021-01044-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-021-01044-7
This article is cited by
-
ETS1 governs pathological tissue-remodeling programs in disease-associated fibroblasts
Nature Immunology (2022)
-
Precision medicine: the precision gap in rheumatic disease
Nature Reviews Rheumatology (2022)
-
Nanotechnology for Enhanced Cytoplasmic and Organelle Delivery of Bioactive Molecules to Immune Cells
Pharmaceutical Research (2022)
-
Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery
Nature Medicine (2022)